Oxford Biomedica
Update in progressOXB.L (LSE)
- Company RatingNeutralCompany RatingCombines sentiment and sustainability signals into an overall assessment of the company.Great · Good · Neutral · At Risk · Poor
- SectorHealthcare
- IndustryBiotechnology
Oxford Biomedica plc is a contract development and manufacturing organization that helps pharma and biotech partners bring therapies to patients worldwide. Its LentiVector platform uses a lentiviral vector to address safety and delivery challenges. It also offers InAAVate, a plug‑and‑play dual‑plasmid transient transfection system, and a standard triple‑transfection system for AAV gene therapies. Based in Oxford, UK, it was formerly Pinco 838 Limited before 1996.
Company score
- Sentiment
- 0.31
- SentimentMeasures the overall tone of recent coverage and discussion about the company.−10 negative · 0 neutral · +10 positive
- Environment
- 0.00
- EnvironmentAssesses the company’s environmental impact, risks, and sustainability practices.−10 negative · 0 neutral · +10 positive
- Social
- 0.12
- Governance
- 0.10
- GovernanceAssesses leadership, accountability, transparency, and business ethics.−10 negative · 0 neutral · +10 positive
- Sustainability
- 0.06
- SustainabilityCombines environmental, social, and governance signals into an overall sustainability score.−10 negative · 0 neutral · +10 positive
- Impact Score
- 0.18
- Impact ScoreCombines sentiment and sustainability performance into an assessment of the company’s overall impact.−10 negative · 0 neutral · +10 positive
Company
- MarketLSE (LSE)
- LocationUnited Kingdom
- CEODr. Frank Mathias
- Founded1996
- Employees977
- Websitewww.oxb.com
Identifiers
- ISINGB00BDFBVT43